PURPOSE: To clarify the need for post-operative radiation treatment in skull base chondrosarcomas (SBCs). METHODS: A retrospective analysis of patients with grade I or II SBC. Patients were divided according to post-surgical treatment strategies: (A) planned upfront radiotherapy and (B) watchful waiting. Tumor control and survival were compared between the treatment groups. The median follow-up after resection was 105 months (range, 9-376). RESULTS: Thirty-two patients (Grade 1, n = 16; Grade 2, n = 16) were included. The most frequent location was petroclival (21, 64%). A gross total resection (GTR) was achieved in 11 patients (34%). Fourteen (44%) underwent upfront radiotherapy (group A) whereas 18 (56%) were followed with serial MRI alone (group B). The tumor control rate for the entire group was 77% and 69% at 10- and 15-year, respectively. Upfront radiotherapy (P = 0.25), extent of resection (P = 0.11) or tumor grade (P = 0.83) did not affect tumor control. The majority of Group B patients with recurrent tumors (5/7) obtained tumor control with repeat resection (n = 2), salvage radiotherapy (n = 2), or a combination of both (n = 1). The 10-year disease-specific survival was 95% with no difference between the group A and B (P = 0.50). CONCLUSION: For patients with grade I/II SBC, a reasonable strategy is deferral of radiotherapy after maximum safe resection until tumor progression or recurrence. At that time, most patients can be successfully managed with salvage radiotherapy or surgery. Late recurrences may occur, and life-long follow-up is advisable.
PURPOSE: To clarify the need for post-operative radiation treatment in skull base chondrosarcomas (SBCs). METHODS: A retrospective analysis of patients with grade I or II SBC. Patients were divided according to post-surgical treatment strategies: (A) planned upfront radiotherapy and (B) watchful waiting. Tumor control and survival were compared between the treatment groups. The median follow-up after resection was 105 months (range, 9-376). RESULTS: Thirty-two patients (Grade 1, n = 16; Grade 2, n = 16) were included. The most frequent location was petroclival (21, 64%). A gross total resection (GTR) was achieved in 11 patients (34%). Fourteen (44%) underwent upfront radiotherapy (group A) whereas 18 (56%) were followed with serial MRI alone (group B). The tumor control rate for the entire group was 77% and 69% at 10- and 15-year, respectively. Upfront radiotherapy (P = 0.25), extent of resection (P = 0.11) or tumor grade (P = 0.83) did not affect tumor control. The majority of Group B patients with recurrent tumors (5/7) obtained tumor control with repeat resection (n = 2), salvage radiotherapy (n = 2), or a combination of both (n = 1). The 10-year disease-specific survival was 95% with no difference between the group A and B (P = 0.50). CONCLUSION: For patients with grade I/II SBC, a reasonable strategy is deferral of radiotherapy after maximum safe resection until tumor progression or recurrence. At that time, most patients can be successfully managed with salvage radiotherapy or surgery. Late recurrences may occur, and life-long follow-up is advisable.
Authors: Adam L Holtzman; Ronny L Rotondo; Michael S Rutenberg; Daniel J Indelicato; Catherine E Mercado; Dinesh Rao; Daryoush Tavanaiepour; Christopher G Morris; Debbie Louis; Stella Flampouri; William M Mendenhall Journal: J Neurooncol Date: 2019-03-02 Impact factor: 4.130
Authors: Arjun Sahgal; Michael W Chan; Eshetu G Atenafu; Laurence Masson-Cote; Gaurav Bahl; Eugene Yu; Barbara-Ann Millar; Caroline Chung; Charles Catton; Brian O'Sullivan; Jonathan C Irish; Ralph Gilbert; Gelareh Zadeh; Michael Cusimano; Fred Gentili; Normand J Laperriere Journal: Neuro Oncol Date: 2014-12-27 Impact factor: 12.300
Authors: Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa Journal: J Clin Neurosci Date: 2009-09-30 Impact factor: 1.961
Authors: Paolo Palmisciano; Gianluca Ferini; Gina Watanabe; Christian Ogasawara; Emal Lesha; Othman Bin-Alamer; Giuseppe E Umana; Kenny Yu; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Ali S Haider Journal: Cancers (Basel) Date: 2022-05-19 Impact factor: 6.575
Authors: Paolo Palmisciano; Ali S Haider; Mohammadmahdi Sabahi; Chibueze D Nwagwu; Othman Bin Alamer; Gianluca Scalia; Giuseppe E Umana; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Kenny Yu; Omar N Pathmanaban Journal: Cancers (Basel) Date: 2021-11-26 Impact factor: 6.639